DrugBank

SEPTEMBER 26, 2024

For instance, Inflectra , a biosimilar of Remicade, underwent a comprehensive clinical development program, including a Phase III trial demonstrating comparable efficacy and safety to the reference product in patients with rheumatoid arthritis. billion by 2028.

Biosimilars 74

Biosimilars Clinical Trials Production FDA 74

The Pharma Data

JANUARY 19, 2021

It hopes to raise about $160 million in aggregate principal amount of 7.375% senior notes due 2025 and $270 million in aggregate principal amount of 7.250% senior notes due 2028. Ortho Clinical Diagnostics is a leader in in vitro diagnostics. It is offering 70 million ordinary shares with a price between $20 and $23 per share.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

JANUARY 25, 2021

Prior to November 1, 2028, the notes will be convertible only upon satisfaction of certain conditions and during certain periods. BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source.

Marketing 52

Marketing Disease Clinical Trials Clinical Development 52

The Pharma Data

NOVEMBER 8, 2020

Likewise, we continue to build an R&D pipeline to make a significant difference in patients’ lives by treating a wide range of skin diseases. Despite the pandemic’s effects on the dermatology business, our portfolio’s key growth drivers, Ilumetri ® , Seysara ® , and Skilarence ® , have improved their performance in Q3.

Licensing 52

Licensing Licensing Production Treatment 52

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. Rare Disease. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52